CAG
HBIO icon

Csenge Advisory Group’s Harvard Bioscience HBIO Stock Holding History

Csenge Advisory Group’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-450
Closed -$16K – 712
2018
Q3 		$16K Buy
+450
New +$25.3K 0.01% 413

Other funds holding HBIO

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Csenge Advisory Group's HBIO Position: Q4 2018 in Review

Csenge Advisory Group sold out of Harvard Bioscience (HBIO) in Q4 2018, closing a stake of 450 shares — an estimated $16K sold.

Csenge Advisory Group first reported a position in HBIO in Q3 2018 and held it in 1 quarter. The position peaked at $16K in Q3 2018. 80 funds tracked by Wall St. Rank hold HBIO as of Q4 2018.

  • Csenge Advisory Group reported no remaining Harvard Bioscience position as of Q4 2018 after selling out during the quarter.
  • Csenge Advisory Group sold 450 Harvard Bioscience shares in Q4 2018, an estimated $16K.
  • Csenge Advisory Group first reported a position in Harvard Bioscience in Q3 2018 and held it in 1 quarter.
  • Csenge Advisory Group's Harvard Bioscience position peaked at $16K in Q3 2018.
  • 80 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2018.

Based on Csenge Advisory Group's 13F filing for Q4 2018, filed 7 Feb 2019.